急性ST段抬高型心肌梗死患者直接PCI后出现无复流的防治新进展

New advances in the prevention and treatment of no-reflow in patients with acute ST-segment elevation myocardial infarction after primary percutaneous coronary intervention

急性ST段抬高型心肌梗死(STEMI)是冠心病的危重类型,可导致严重的心血管事件,甚至危及生命。直接经皮冠状动脉介入(PCI)治疗是最有效开通闭塞相关动脉并恢复心肌灌注的治疗措施,然而,有时尽管成功开通了闭塞相关动脉,仍有一部分患者出现冠脉无复流现象,无复流往往是预后不良的独立危险因素。无复流的病理生理机制是复杂的,并且与多种因素密切相关,因此,如何早期预测及诊断无复流,及时有效的采取相应治疗策略,这在临床上具有重大意义。

Acute ST-segment elevation myocardial infarction is a critical type of coronary heart disease,which can lead to serious cardiovascular events and is even life-threatening.Primary percutaneous coronary intervention is the most effective treatment measure to open the occluded related arteries and restore myocardial perfusion.However,sometimes despite the successful opening of the occluded related arteries,a proportion of patients still have no-reflow.No-reflow is often an independent risk factors for poor prognosis.The pathophysiological mechanism of no-reflow is complex and closely related to many factors.Therefore,how to predict and diagnose no-reflow at an early stage and adopt corresponding treatment strategies in a timely and effective manner is of great clinical significance.